

Atezolizumab IMbrave150

### PRELIMINARY SCORE

#### CURATIVE




#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



Delayed deterioration in global QoL

#### Serious and disabling adverse effects




#### Other adjustments



Atezolizumab IMbrave150

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Gastrointestinal Cancers  
 Therapeutic Indication: Advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy  
 Experimental Arm: Atezolizumab + Bevacizumab  
 Control Arm: Sorafenib

